丹麦、法国、荷兰和西班牙2022年男性历史天花疫苗接种对II分支猴痘的有效性
2022年全球猴痘病毒II分支疫情主要发生于男男性行为者。研究纳入丹麦、法国、荷兰和西班牙2022年8月1日前发病、出生于各国天花疫苗接种运动高峰期的男性猴痘病例,用Farrington筛查法逻辑回归估计疫苗有效性(VE),随机效应模型合并。各国VE差异大(40-80%,I2=82%),合并VE为70%(95%CI:23-89%),提示历史天花疫苗对II分支猴痘有残余交叉保护,但不确定性高、异质性大。
要点
- 丹麦、法国、荷兰和西班牙历史天花疫苗接种覆盖率在1960年代末前高达80-90%。
- 各国VE估计差异大(40-80%,I2=82%),合并VE为70%(95%CI:23-89%)。
- 作者建议高风险暴露者按国家推荐接种猴痘疫苗,无论既往天花疫苗史,直至有新证据。
核心结论
- 历史天花疫苗接种对男性II分支猴痘病毒所致猴痘可能提供残余交叉保护,但不确定性高且异质性大。
- 高风险暴露者应按国家推荐接种猴痘疫苗,无论既往天花疫苗史,直至进一步证据出现。
- 亟需在受猴痘病毒I分支疫情影响的撒哈拉以南非洲国家开展类似研究。
研究设计与样本
- 纳入丹麦、法国、荷兰和西班牙2022年8月1日前发病、出生于各国天花疫苗接种运动高峰期(最晚1971年)的男性实验室确诊猴痘病例。
- 使用Farrington筛查法逻辑回归估计各国疫苗有效性(VE)及95%CI,并用随机效应模型计算合并估计值。
主要发现
- 丹麦、法国、荷兰和西班牙历史天花疫苗接种覆盖率在1960年代末前高达80-90%。
- 各国VE估计差异大(40-80%,I2=82%),可能反映不同加强策略。
- 合并VE估计为70%(95%CI:23-89%)。
关键数值与推荐
- VE估计范围为40-80%(I2=82%)。
- 合并VE为70%(95%CI:23-89%)。
临床怎么用
- 作者建议高风险暴露者应按国家推荐接种猴痘疫苗,无论既往天花疫苗史,直至进一步证据出现。
局限性
- 合并VE估计不确定性高(95%CI:23-89%)。
- 各国VE估计异质性大(I2=82%)。
- 作者指出需进一步证据,并亟需在撒哈拉以南非洲国家开展类似研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundIn 2022, a global monkeypox virus (MPXV) clade II epidemic occurred mainly among men who have sex with men. Until early 1980s, European smallpox vaccination programmes were part of worldwide smallpox eradication efforts. Having received smallpox vaccine > 20 years ago may provide some cross-protection against MPXV.AimTo assess the effectiveness of historical smallpox vaccination against laboratory-confirmed mpox in 2022 in Europe.MethodsEuropean countries with sufficient data on case vaccination status and historical smallpox vaccination coverage were included. We selected mpox cases born in these countries during the height of the national smallpox vaccination campaigns (latest 1971), male, with date of onset before 1 August 2022. We estimated vaccine effectiveness (VE) and corresponding 95% CI for each country using logistic regression as per the Farrington screening method. We calculated a pooled estimate using a random effects model.ResultsIn Denmark, France, the Netherlands and Spain, historical smallpox vaccination coverage was high (80-90%) until the end of the 1960s. VE estimates varied widely (40-80%, I2 = 82%), possibly reflecting different booster strategies. The pooled VE estimate was 70% (95% CI: 23-89%).ConclusionOur findings suggest residual cross-protection by historical smallpox vaccination against mpox caused by MPXV clade II in men with high uncertainty and heterogeneity. Individuals at high-risk of exposure should be offered mpox vaccination, following national recommendations, regardless of prior smallpox vaccine history, until further evidence becomes available. There is an urgent need to conduct similar studies in sub-Saharan countries currently affected by the MPXV clade I outbreak.
引用
- Colombe S, Funke S, Koch A, et al. Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022. Euro Surveill. 2024. PMID: 39176988. doi:10.2807/1560-7917.ES.2024.29.34.2400139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。